Brussels-based Candriam has launched a fund investing in listed companies that develop products and services for cancer treatment.
Candriam Equities L Oncology Impact will donate 10% of its management fee to various European cancer research institutes. The institutional management fee is 0.8%.
Candriam announced the fund on Monday, February 4, which was World Cancer Day.
The firm described cancer as an epidemic and the second-leading cause of death globally.
However, as innovation in cancer treatments is “catching up”, it also impacts a significant number of sectors, such as biotech, pharmaceuticals, artificial intelligence and research.
The fund supports the development of a wide range of cancer diagnostics and treatments and wants to identify those breakthrough innovations that are changing the way cancer is treated, said the firm.
Rudi Van den Eynde, Candriam’s head of thematic equity, said: “We see a lot of innovation in the treatment of many diseases and particularly cancer. We want to identify those companies with strong growth potential.”
The fund’s team boasts two PhD level analysts and will be backed by an independent advisory board “with leading scientists in the oncology field”.
The Luxembourg-domiciled fund is currently licensed for distribution in Luxembourg, Austria, Switzerland, Germany, Spain, France, the United Kingdom, Italy, the Netherlands and Portugal.
©2019 funds europe
